The presence of these metabolic abnormalities in obese NAFLD patients may necessitate more intensive management strategies, including targeted interventions to improve insulin sensitivity and reduce cardiovascular risk. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.